RECENT Healthcare RESEARCH
According to a recent report by the Wall Street Journal, America’s largest pharmacy chain, CVS Health (CVS), is in talks to buy Aetna (AET) for more than $66 billion.
For 3Q17, Wall Street analysts estimate that Pfizer will report EPS (earnings per share) of $0.64 on revenues of $13.18 billion.
Allergan (AGN) is one of the leading pharmaceutical companies, and it’s set to release its 3Q17 earnings on November 1.
As of October 26, of the 18 brokerage companies covering ISRG stock, 11 (~61%) recommend a “buy,” while six (~33%) recommend a “hold.”
In 3Q17, Vertex Pharmaceuticals (VRTX) generated revenues of $578.0 million, which was a ~40.0% rise YoY and a ~6.0% rise QoQ.
In its 2Q17 earnings conference call, Ionis Pharmaceuticals (IONS) raised its guidance for 2017 pro forma operating income.
In 3Q17, Biogen (BIIB) generated revenue of ~$3.1 billion, which reflected ~4% growth year-over-year.
Bristol-Myers Squibb (BMY) is set to release its 3Q17 earnings on October 27, 2017. Analysts estimate the company will post EPS of $0.77 and revenues of $5,196 million for 3Q17.
In 1H17, AbbVie (ABBV) reported revenues of around $13.5 million, compared to $12.4 million in 1H16. In 1Q17 and 2Q17, AbbVie reported revenues of around $6.5 million and $6.9 million, respectively.
Analysts estimate Merck’s gross profit margin to come in at 75.8% for 3Q17, a 0.5% increase as compared to its gross profit margin in 3Q16.
For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.
In 1H17, Valeant Pharmaceuticals International (VRX) reported revenues of $4.3 billion compared to $4.7 billion in 1H16. In 2Q17, its revenues were $2.2 billion.
Gilead Sciences stock has risen ~15.2% in 3Q17 and 13.9% year-to-date as of October 20, 2017.
BSX stock has been performing well recently, and investor confidence appears to have ridden on innovative product launches and strong 2Q17 results.
Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”
In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.
In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million.
On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.
Johnson & Johnson (JNJ) is set to release its 3Q17 earnings on October 17. Analysts expect JNJ’s 3Q17 revenues to rise ~8.3% to ~$19.3 billion compared to ~$17.8 billion for 3Q16.